GW Pharmaceuticals
E874301
GW Pharmaceuticals is a biopharmaceutical company known for pioneering cannabis-based prescription medicines, including the epilepsy treatment Epidiolex.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| acquiredBy | Jazz Pharmaceuticals NERFINISHED ⓘ |
| acquisitionDate | 2021-05-05 ⓘ |
| acquisitionValue | 7200000000 USD ⓘ |
| country | United Kingdom ⓘ |
| delistedFrom |
London Stock Exchange
NERFINISHED
ⓘ
NASDAQ NERFINISHED ⓘ |
| develops | cannabinoid-based prescription medicines ⓘ |
| EpidiolexActiveIngredient | cannabidiol ⓘ |
| EpidiolexFormulation | oral solution ⓘ |
| EpidiolexIndication |
Dravet syndrome
NERFINISHED
ⓘ
Lennox-Gastaut syndrome NERFINISHED ⓘ tuberous sclerosis complex ⓘ |
| focusesOn |
multiple sclerosis symptom management
ⓘ
rare and severe forms of epilepsy ⓘ |
| formerHeadquartersLocation | Porton Down, Wiltshire, United Kingdom NERFINISHED ⓘ |
| foundedBy |
Brian Whittle
NERFINISHED
ⓘ
Geoffrey Guy NERFINISHED ⓘ |
| hasSubsidiary | GW Research Ltd NERFINISHED ⓘ |
| headquartersLocation | Cambridge, United Kingdom NERFINISHED ⓘ |
| inception | 1998 ⓘ |
| industry |
biotechnology industry
ⓘ
pharmaceutical industry ⓘ |
| legalForm | public limited company ⓘ |
| listedOn | London Stock Exchange NERFINISHED ⓘ |
| locatedInTimeZone | Europe/London ⓘ |
| notableFor | first FDA-approved plant-derived cannabinoid medicine ⓘ |
| notableProduct |
Epidiolex
NERFINISHED
ⓘ
Sativex NERFINISHED ⓘ |
| parentOrganization | Jazz Pharmaceuticals NERFINISHED ⓘ |
| partOf | cannabis industry ⓘ |
| regulatoryApproval |
Epidiolex EMA approval 2019
ⓘ
Epidiolex FDA approval 2018 ⓘ Sativex approvals in multiple countries ⓘ |
| regulatoryBodyInteraction |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| researchArea |
cannabinoid science
ⓘ
central nervous system disorders ⓘ |
| SativexActiveIngredients |
cannabidiol
ⓘ
tetrahydrocannabinol ⓘ |
| SativexFormulation | oromucosal spray ⓘ |
| SativexIndication | multiple sclerosis spasticity ⓘ |
| specializesIn |
cannabis-based medicines
ⓘ
epilepsy treatments ⓘ neurology ⓘ |
| stockExchange | NASDAQ ⓘ |
| tickerSymbol | GWPH NERFINISHED ⓘ |
| website | https://www.gwpharm.com/ ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.